Unchanged pharmacokinetics of VP-16-213 (etoposide, NSC 141540) during concomitant administration of doxorubicin and cyclophosphamide
- 30 June 1987
- journal article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 23 (6) , 807-811
- https://doi.org/10.1016/0277-5379(87)90283-5
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Pharmacokinetics of high dose etoposide (VP 16–213)European Journal of Cancer and Clinical Oncology, 1986
- Inactivation of φX174 DNA by the ortho-quinone derivative or its reduction product of the antitumor agent VP 16-213European Journal of Cancer and Clinical Oncology, 1985
- Etoposide (VP-16–213)New England Journal of Medicine, 1985
- Plasma assay for the antineoplastic agent VP 16-213 (etoposide) using high-performance liquid chromatography with electrochemical detectionJournal of Pharmaceutical and Biomedical Analysis, 1983
- Protein binding of anthraquinone glycosides, with special reference to adriamycinCancer Chemotherapy and Pharmacology, 1982
- Pharmacokinetics of VP16-213 given by different administration methodsCancer Chemotherapy and Pharmacology, 1982
- Design and characterization of a coulometric detector with a glassy carbon electrode for high-performance liquid chromatographyJournal of Chromatography A, 1976
- EPEG, a new antineoplastic epipodophyllotoxinClinical Pharmacology & Therapeutics, 1975